Amyris (NASDAQ:AMRS) Price Target Raised to $4.00 at Piper Sandler

Amyris (NASDAQ:AMRSGet Rating) had its price target upped by Piper Sandler from $2.50 to $4.00 in a research note issued to investors on Monday, The Fly reports. Piper Sandler currently has a neutral rating on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the company. Roth Capital cut Amyris from a buy rating to a neutral rating in a research note on Wednesday, August 10th. JPMorgan Chase & Co. initiated coverage on Amyris in a research note on Friday, June 24th. They set a neutral rating for the company.

Amyris Trading Up 11.6 %

AMRS opened at $3.95 on Monday. The stock has a market cap of $1.27 billion, a PE ratio of -2.62 and a beta of 1.36. The company has a quick ratio of 1.13, a current ratio of 1.66 and a debt-to-equity ratio of 1.26. The business has a 50 day moving average of $2.73 and a 200-day moving average of $3.03. Amyris has a 52 week low of $1.47 and a 52 week high of $15.12.

Amyris (NASDAQ:AMRSGet Rating) last released its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The firm had revenue of $65.20 million during the quarter, compared to the consensus estimate of $81.53 million. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) EPS. Equities research analysts predict that Amyris will post -1.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amyris news, Director Frank Kung sold 1,080,676 shares of Amyris stock in a transaction on Monday, September 19th. The stock was sold at an average price of $3.80, for a total value of $4,106,568.80. Following the completion of the sale, the director now owns 109,460 shares of the company’s stock, valued at approximately $415,948. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Frank Kung sold 1,080,676 shares of Amyris stock in a transaction on Monday, September 19th. The stock was sold at an average price of $3.80, for a total value of $4,106,568.80. Following the completion of the sale, the director now owns 109,460 shares of the company’s stock, valued at $415,948. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Melo sold 55,576 shares of Amyris stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $2.12, for a total value of $117,821.12. Following the completion of the sale, the chief executive officer now directly owns 492,701 shares of the company’s stock, valued at approximately $1,044,526.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,615,285 shares of company stock valued at $10,210,649. Corporate insiders own 33.80% of the company’s stock.

Institutional Trading of Amyris

Large investors have recently modified their holdings of the company. Gordian Capital Singapore Pte Ltd bought a new stake in Amyris during the fourth quarter valued at about $26,000. Point72 Hong Kong Ltd bought a new stake in Amyris during the second quarter valued at about $29,000. Hudock Inc. bought a new stake in Amyris during the first quarter valued at about $31,000. Rafferty Asset Management LLC bought a new stake in Amyris during the second quarter valued at about $37,000. Finally, Prospera Financial Services Inc bought a new stake in Amyris during the first quarter valued at about $39,000. Institutional investors own 43.08% of the company’s stock.

Amyris Company Profile

(Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Recommended Stories

The Fly logo

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.